Benedito Barraviera, Full Professor, Center for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP), Botucatu, SP, Brazil.
The Center for the Study of Venoms and Venomous Animals (CEVAP) of UNESP, since its launch in 1993, aims to develop translational research by working from bench to bedside with biopharmaceuticals derived from animal venoms.
Pursuing such goal, in 2010, support was received from the Department of Science and Technology (Decit) of the Brazilian Ministry of Health to finance the phase I/II clinical trial Treatment of chronic venous ulcers with fibrin sealant derived from snake venom. In 2013, another phase I/II clinical trial was approved by Decit, the “Treatment of envenoming by massive Africanized honeybees (Apis mellifera) stings with the new apilic antivenom”. Both trials were previously approved by the National Committee on Research Ethics (CEP/CONEP), were recognized by Anvisa and ended in 2019.
All reports concerning those clinical trials were sent to the respective regulatory bodies and results were published in peer-reviewed journals of high impact factor1, 2, 3, 4. The following videos give further information on the process of developing and producing both products.
Video 1. The fibrin sealant developed by CEVAP/UNESP.
Video 2. The apilic antivenom developed by CEVAP/UNESP.
The accumulated experience in the development of these biopharmaceuticals for the last ten years has stimulated the next challenges that include carrying out the phase III clinical trials. Therefore, samples produced in pilot scale must follow good manufacturing practices (GMP). Since up to this moment there is no available infrastructure in Brazil for the production of such samples, the researchers of CEVAP submitted to the Ministry of Health a project to build a Factory for the Production of Pilot Batches for Clinical Research5, which was approved in 2019. In February of 2022, the construction of this facility has begun on Lageado Experimental Farm, an UNESP campus in Botucatu, SP.
The creation of both biopharmaceuticals has broaden the horizons of public universities in Brazil, making possible the construction of a contract development and manufacturing organization (CDMO) in a research center. Thus, CEVAP will become soon an “industry” with two clear branches: an educational facility that will train professionals capable of working on the production chain of biological products from bench to bedside; and an “industrial” facility for the production of biopharmaceutical samples for clinical research, both for public and private initiatives.
This pioneering initiative in Latin America will contribute to the formation of professionals capable of crossing the “death valley”6, 7, 8 and to the establishment of biopharma innovation ecosystems that will, in turn, create startups that will bring more wealth to the country9.
Image: Author.
Figure 1. Packaging of the fibrin sealant developed by CEVAP/UNESP. Image by CEVAP/UNESP.
Image: Author.
Figure 2. Packaging of the apilic antivenom developed by CEVAP/UNESP. Image by CEVAP/UNESP.
BARRAVIERA, B. Biopharmaceutical products born in a Brazilian public university [online]. SciELO in Perspective | Press Releases, 2022 [viewed ]. Available from: https://pressreleases.scielo.org/en/2022/06/08/biopharmaceutical-products-born-in-a-brazilian-public-university/
The Center for the Study of Venoms and Venomous Animals (CEVAP) of UNESP, since its launch in 1993, aims to develop translational research by working from bench to bedside with biopharmaceuticals derived from animal venoms.
Recent Comments